Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF) (2016 - 2025)

Abeona Therapeutics has reported Depreciation & Amortization (CF) over the past 15 years, most recently at $863000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $863000.0 for Q4 2025, up 60.11% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (up 27.2% YoY), and the annual figure for FY2025 was $2.5 million, up 27.2%.
  • Depreciation & Amortization (CF) for Q4 2025 was $863000.0 at Abeona Therapeutics, up from $608000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ABEO hit a ceiling of $863000.0 in Q4 2025 and a floor of $16000.0 in Q2 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $611500.0 (2023), compared with a mean of $618700.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 98.08% in 2021 and later skyrocketed 4731.25% in 2022.
  • Abeona Therapeutics' Depreciation & Amortization (CF) stood at $807000.0 in 2021, then fell by 9.67% to $729000.0 in 2022, then tumbled by 32.65% to $491000.0 in 2023, then rose by 9.78% to $539000.0 in 2024, then skyrocketed by 60.11% to $863000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $863000.0 (Q4 2025), $608000.0 (Q3 2025), and $544000.0 (Q2 2025) per Business Quant data.